Back to Search
Start Over
Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19.
- Source :
-
Clinical nephrology. Case studies [Clin Nephrol Case Stud] 2022 Jan 05; Vol. 10, pp. 6-10. Date of Electronic Publication: 2022 Jan 05 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- . Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection.<br /> (© Dustri-Verlag Dr. K. Feistle.)
Details
- Language :
- English
- ISSN :
- 2196-5293
- Volume :
- 10
- Database :
- MEDLINE
- Journal :
- Clinical nephrology. Case studies
- Publication Type :
- Report
- Accession number :
- 35028280
- Full Text :
- https://doi.org/10.5414/CNCS110567